WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences
May 16, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 16, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce...
WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project
March 07, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to...
WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary
February 09, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1) announces that the Company’s board of directors (the “Board”)...
WPD Pharmaceuticals Announces Appointment of New Director
February 03, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that the Company appointed Mr....
WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity
February 01, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 01, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), announced that in respect to its sublicense agreement with...
WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech
January 25, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that it has entered into an amended...
WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML
December 16, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals Announces AGSM Results
October 01, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Oct. 01, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces the results...
WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland
September 02, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces that it...
WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
July 12, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...